{
    "clinical_study": {
        "@rank": "163147", 
        "acronym": "VCU-Alpha1RT", 
        "arm_group": {
            "arm_group_label": "Alpha-1 anti-trypsin (AAT)", 
            "arm_group_type": "Experimental", 
            "description": "We will use plasma derived AAT 60 mg/Kg, single infusion, within 12 hours of hospital admission for ST-segment elevation myocardial infarction (STEMI)"
        }, 
        "brief_summary": {
            "textblock": "Acute myocardial infarction is characterized by an intense inflammatory response.\n\n      The degree of the response influences clinical outcome, with 'more' inflammation promoting\n      heart failure. In this study we plan to determine whether treatment with plasma derived\n      alpha-1 antitrypsin will quench the inflammatory response in patients with acute ST-segment\n      elevation myocardial infarction (STEMI)."
        }, 
        "brief_title": "Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and\n             ECG evidence of ST segment elevation (>1 mm) in 2 or more anatomically contiguous\n             leads that is new or presumably new\n\n          -  Planned or completed coronary angiogram for potential intervention\n\n          -  Age>21\n\n        Exclusion Criteria:\n\n          -  Inability to give informed consent\n\n          -  Hemodynamic instability as defined as need for inotropic or vasoactive agents, or\n             need for mechanical support devices (including intra-aortic balloon pump)\n\n          -  Pregnancy\n\n          -  Preexisting congestive heart failure (AHA/ACC class C-D, New York Heart Association\n             III-IV)\n\n          -  Preexisting severe left ventricular dysfunction (EF<20%)\n\n          -  Preexisting severe valvular heart disease\n\n          -  Known active infections (acute or chronic)\n\n          -  Recent (<14 days) or active use of anti-inflammatory drugs (not including NSAIDs or\n             corticosteroids used for IV dye allergy only)\n\n          -  Known chronic inflammatory disease (including but not limited to rheumatoid\n             arthritis, systemic lupus erythematosus)\n\n          -  Known active malignancy of any type, or prior diagnosis in the past 10 years\n\n          -  Anticipated need for cardiac or major surgery\n\n          -  Known active cancer (or prior diagnosis of cancer within the past 10 years)\n\n          -  Known Immunoglobulin A (IgA) deficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936896", 
            "org_study_id": "HM15342"
        }, 
        "intervention": {
            "arm_group_label": "Alpha-1 anti-trypsin (AAT)", 
            "intervention_name": "Alpha 1-Antitrypsin", 
            "intervention_type": "Drug", 
            "other_name": [
                "Prolastin C", 
                "Aralast NP"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Alpha 1-Antitrypsin", 
                "Protein C Inhibitor"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Acute myocardial infarction", 
            "Heart Failure", 
            "Inflammation"
        ], 
        "lastchanged_date": "December 18, 2013", 
        "location": {
            "contact": {
                "email": "aabbate@vcu.edu", 
                "last_name": "Antonio Abbate, MD, PhD", 
                "phone": "804-828-0513"
            }, 
            "facility": {
                "address": {
                    "city": "Richmond", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "23298"
                }, 
                "name": "Virginia Commonwealth University"
            }, 
            "investigator": {
                "last_name": "Antonio Abbate, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Alpha-1 Anti-Trypsin (AAT) to Quench the Acute Inflammatory Response in ST-segment Elevation Acute Myocardial Infarction", 
        "other_outcome": {
            "description": "We will record the number of participants with all adverse events (cardiac and non-cardiac) over the 3 months, including infusion reactions and drug-related issues.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "overall_contact": {
            "email": "aabbate@vcu.edu", 
            "last_name": "Antonio Abbate, MD, PhD", 
            "phone": "8048280513"
        }, 
        "overall_contact_backup": {
            "email": "bvantassell@vcu.edu", 
            "last_name": "Benjamin W Van Tassell, PharmD", 
            "phone": "8049820997"
        }, 
        "overall_official": [
            {
                "affiliation": "Virginia Commonwealth University", 
                "last_name": "Antonio Abbate, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Virginia Commonwealth University", 
                "last_name": "Benjamin Van Tassell, PharmD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: IRB Panel D, Virginia Commonwealth University"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Area under the curve for C reactive protein (CRP) drawn at admission, 3 days and 14 days", 
            "measure": "C reactive protein", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936896"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "We will calculate the interval change between admission and 3 months in left ventricular end-systolic volume, using echocardiography", 
            "measure": "Left ventricular end-systolic volume change", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Virginia Commonwealth University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Virginia Commonwealth University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}